Beyond the finish line
If any moment symbolizes Olympic runner ’ career, it is a roundtable with his fellow chemistry majors during his senior year at to discuss their future plans. “At least 80 percent of my class was going on to pursue a Ph.D. in chemistry or a M.D.,” remembers Symmonds. “When they got to me, I said I was gonna stop everything and train for the 2008 Olympics.”

The snickering and eye rolls from his classmates didn’t deter Symmonds. “I knew even if I never made the team, I had to take the risk, or I wouldn’t be able to look back and have been proud of myself for not at least trying,” he says.
The risk turned out to be worth it, as Symmonds has become one of the most successful American runners of his generation. Yet the lessons he learned as a biochemistry major have been an integral part of his success.
Growing up, Symmonds always expected to become a surgeon like his father. “The reason why I was a biochemistry major was because it had the best success rate of getting people into medical school, and that’s what I wanted to do,” he says.
But he found something that attracted him even more than medicine: running. Symmonds had started running competitively in middle school. By the time he graduated high school, Symmonds had won state championships in the 800-, 1600- and 3200-meter races, along with the 4x400-meter relay race.
He decided to enroll at Willamette University, a small liberal-arts school in Salem, Ore. As he writes in his autobiography, “,” the track coaches at Willamette insisted that he would “be a student-athlete, not the other way around.”
At first, Symmonds devoted equal effort to his coursework and athletics. (He won the national championship in the 800 for each of his four years at Willamette.) But as Symmonds’ running aspirations grew, the rigors of a science major became too burdensome. “My senior year, I decided that if I was going to have a push for the 2008 Olympics, I really had to reevaluate my priorities,” he says.
That meant his academic performance had to suffer. “I had terrible grades my senior year,” he remembers. But Symmonds says he doesn’t regret taking on the demanding workload of a challenging major like biochemistry, pointing out that “chipping away piece by piece and ultimately coming to the right answer taught me even the most insurmountable challenges can be broken down and tackled eventually.”
Willamette’s faculty noted Symmonds’ ability to put his nose to the grindstone. “I think Nick would have made a very good biochemist,” states , Symmonds’ adviser in the chemistry department. “His level of understanding and his work ethic were quite good.” In fact, Silverstein points out, Symmonds “accomplished more on our ongoing enzyme inhibition project than any other previous student, with perhaps one exception.”
Such determination and dedication served Symmonds well on the track, where he became the second-ranked American runner at 800 meters during his senior year in college. His achievements caught the attention of Nike, which signed him to a sponsorship deal that allowed him to focus all of his energy on training after he graduated in 2006. He won the 800 meters at the 2008 U.S. Olympic Trials, earning his ticket to the Olympics.

In Beijing, Symmonds ran a disappointing race in the semifinal qualifying round and failed to advance to the final. He spent the next four years determined to make amends. In 2012, Symmonds qualified for the Summer Olympics in London. This time, he advanced all the way to the final, where he ran a personal best time of 1 minute, 42.95 seconds, which would have won a medal at any of the previous Games. But four runners were even faster (including Kenyan David Rudisha, who won the gold medal with a world-record time of 1:40.91), leaving Symmonds without a medal.
“That,” Symmonds admits, “was a hard pill to swallow.” Despite that heartbreak, Symmonds is back at it, currently training to compete at the . “I think that would be a really nice way to round out a perfect decade of running.”
His experiences in Beijing and London have given Symmonds a unique perspective on what it means to be an Olympian. “On one hand, we’re put on a pedestal, and we’re expected to be positive role models and win medals for the country. But,” he adds, “that’s about all that the public wants from us.”
Symmonds rejects the idea that success or failure at the Olympics is all that athletes should be judged by. “Many Olympians have really interesting, diverse backgrounds and are qualified to do many things,” he says.
In 2014, Symmonds published his autobiography and is exploring the world of entrepreneurship after inventing , a chewing gum infused with caffeine, taurine and B vitamins. The product “may be the closest I’ve come to actually utilizing my degree in chemistry,” says Symmonds.
Such words would make his former adviser smile. “We take great pride in our graduates,” says Silverstein. “The fact that a few of them go on to be among the best in the world in their field is extra gravy.”
As for his former teammates at Willamette, Symmonds claims that they are equally supportive. “They tell me that they knew I had the talent to be this good all along. That part surprised me!”
Should make for an interesting 10-year college reunion.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

In memoriam: Ralph G. Yount
He was a professor emeritus of chemistry and biochemistry at Washington State University and an ASBMB member for 58 years.

From dust to discovery
From makeshift classrooms in Uganda to postdoctoral research in Chicago, MOSAIC scholar Elizabeth Kaweesa builds a legacy in women鈥檚 health.

Fliesler wins scientific and ethical awards
He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥� to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥� and just getting started.

ASBMB members recognized as Allen investigators
Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.